Short answer
Bristol Myers Squibb (BMY) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $13.0B (up 5.7% year over year) with net income of $3.3B.
Q2 2026 key financials · XBRL
- Revenue
- $13.0B
- +5.7% YoY · +12.9% QoQ
- Net income
- $3.3B
- +153.2% YoY · +23.9% QoQ
- EPS (diluted)
- $1.62
- +149.2% YoY · +23.7% QoQ
Source: XBRL data from the Bristol Myers Squibb (BMY) Q2 2026 10-Q on SEC EDGAR. USD.
Bristol Myers Squibb Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Filing text provides no quarterly revenue or year-over-year comparison
- Filing text provides no profitability, margin, or segment performance figures
- 2026 pipeline progress: iberdomide and mezigdomide NDA acceptances; Camzyos adolescent sNDA acceptance
- May 2026 Hengrui collaboration covering 13 early-stage oncology, hematology, and immunology assets
- Sotyktu approved for PsA; Opdivo approved for cHL in U.S. and EU
Risk Factors
- No material changes to risk factors disclosed in the 2025 Form 10-K
- Carried-forward regulatory and compliance risks unchanged from the 2025 Form 10-K
- Carried-forward operational and competitive risks unchanged from the 2025 Form 10-K
- Carried-forward financial risks unchanged from the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bristol Myers Squibb quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.